当地时间8月11日，世卫组织宣布将新增测试3种药物，用于治疗新冠肺炎。这项测试将在全球52个国家的600余座医院内进行。
According to a press release issued by WHO on Wednesday, the three new drugs are artesunate, a treatment for severe malaria; imatinib, a drug for certain cancers; and infliximab, a treatment for immune system disorders such as Crohn's Disease.
世卫组织在8月11日的新闻稿中称，3种药物分别是用于治疗严重疟疾的青蒿琥酯、用于治疗某种癌症的药物伊马替尼、以及用于治疗免疫系统紊乱如克罗恩病的英夫利西单抗。
These therapies were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients, and they were donated for the trial by their manufacturers, WHO said.
这些药物是由一个独立专家小组根据其在降低新冠肺炎住院患者死亡风险方面的潜力选择的，药物由制造商为试验捐赠。
"Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need, and WHO is proud to lead this global effort," said WHO Director-General Tedros Adhanom Ghebreyesus.
世卫组织总干事谭德塞说："为新冠肺炎患者找到更多有效和可获得的治疗方法仍然是一项关键需求，世卫组织为领导这一全球努力感到自豪。"
